Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Filings
41 filings of POLYMED since February 2025; the newest 40 below.
board outcome 13, presentation 13, transcript 10, results 2, acquisition 1, dividend 1
| Filed | Type | Subject | |
|---|---|---|---|
| 11 Nov 2026 | transcript Capex, Guidance, Results | Poly Medicure Limited has informed the Exchange about Transcript of Earning Call held on 05th November, 2026AI summaryPoly Medicure filed the transcript of its Q2 and H1 FY27 earnings conference call held on 05 November 2026, on unaudited results for the quarter and half year ended 30 September 2026. Management said H1 standalone revenue was INR919 crores (up 15%) with PAT of INR180 crores; Q2 standalone revenue was INR488 crores (up 17%) with PAT of INR92 crores. Consolidated H1 revenue was INR1,106 crores (up 31%), or 14% organically; consolidated Q2 revenue was INR581 crores (up 31%) with PAT of INR95 crores. Management reaffirmed FY27 consolidated revenue guidance of INR2,300-2,400 crores and standalone revenue guidance of INR1,900-1,950 crores, raised standalone EBITDA margin guidance to 26%-27.5% from 25%-27%, and kept capex guidance at INR200-225 crores, with INR124 crores spent in H1. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2026 | presentation Guidance, Results | Poly Medicure Limited has informed the Exchange about Investor PresentationAI summaryPoly Medicure Limited filed its investor presentation on unaudited standalone and consolidated financial results for the second quarter ended September 30, 2026, under Regulation 30 and Regulation 51 of the SEBI Listing Regulations. Consolidated FY26 operating revenue was Rs 1,875 crore, with India at Rs 997 crore, Europe at Rs 187 crore and RoW at Rs 691 crore; FY26 EBITDA was Rs 458 crore. The presentation describes the company as the largest listed medical devices player in India and the largest exporter of medical consumables, with 15 plants across 5 countries. Management states a target of revenue 2x by 2030 and cash of Rs 839 crore as on September 30, 2026, and says FY27 onwards focuses on organic and inorganic expansion. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Nov 2026 | board outcome Legal, Results | Poly Medicure Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryPoly Medicure Limited's board approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, with Auditors' Review Reports attached as Annexure A. The board classified Poly Medicure B.V., Netherlands, a wholly owned subsidiary, as a Material Subsidiary of the Company, as its net worth exceeded 10% of the consolidated net worth. The board meeting started at 11:30 A.M. and concluded at 2:00 P.M. on 5 November 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2026 | transcript Acquisition, Capex, Guidance, Management change, Results | Poly Medicure Limited has informed the Exchange about TranscriptAI summaryPoly Medicure submitted the transcript of its Q1 FY27 earnings conference call held on 10 August 2026, on unaudited results for the quarter ended 30 June 2026 (board approval 7 August 2026). Management said standalone revenue for Q1 was INR431 crores, up 12.3%, and consolidated revenue was INR525 crores, up 30.3% (organic up 12.4%); consolidated operating EBITDA margin was 24.1%. Management maintained FY27 consolidated revenue guidance of INR2,300-2,400 crores and standalone revenue guidance of INR1,900-2,000 crores, with standalone EBITDA margin of 25-27% and capex of INR200-225 crores. Management said Middle East sales fell 32% due to the West Asia crisis and shipping disruption, and that it aims to double revenue by FY30 under its "PolyMed 3.0" strategy. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Aug 2026 | presentation Acquisition, Capex, Results | Poly Medicure Limited has informed the Exchange about Investor PresentationAI summaryPoly Medicure Limited filed its investor presentation on Q1 FY27 unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, dated August 7, 2026. The presentation shows FY26 operating revenue of Rs 1,875 crore, up from Rs 687 crore in FY20 (18% CAGR), with EBITDA of Rs 458 crore in FY26. FY26 revenue by segment: Infusion Therapy Rs 997 crore, Renal Rs 187 crore and Others Rs 691 crore; by geography: India Rs 582 crore, Europe Rs 597 crore and RoW Rs 696 crore. The company describes itself as the 2nd largest medical devices player in India and the largest exporter of medical consumables, with 15 manufacturing plants across 5 countries. The presentation states the company has around Rs 850 crore of cash and plans organic and inorganic expansion under its FY27-onwards "Ascent" phase. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Aug 2026 | board outcome Dividend / buy-back, Management change, Results | Poly Medicure Limited has informed the outcome of Board Meeting held on today i.e. 07th August, 2026 and submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryBoard of Poly Medicure Limited, at its meeting held on 07 August 2026 in Jaipur, approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. Standalone total income for Q1 FY27 was Rs 45,974.91 lakh and standalone profit after tax was Rs 8,812.33 lakh; consolidated total income was Rs 55,878.45 lakh and consolidated profit after tax was Rs 8,527.43 lakh. The board also approved grant of 1,476 stock options and allotment of 1,975 equity shares under the Employee Stock Option Scheme 2020. Paid-up equity share capital increased to Rs 50,68,07,325 after the allotment, and the board re-appointed M/s Jai Prakash & Company as Cost Auditors for FY 2026-27. Deputy Company Secretary and Compliance Officer Mr. Ravi Prakash resigned, effective close of business on 10 August 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 26 Jun 2026 | credit rating Rating | Poly Medicure Limited has informed the Exchange about Credit Rating- Outlook Revision and Rating Re-affirmedAI summaryPoly Medicure Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, disclosing credit ratings assigned or reaffirmed by CRISIL Ratings Limited. CRISIL Ratings, in a letter dated June 25, 2026, revised the long-term rating outlook to Positive from Stable and reaffirmed the long-term rating at Crisil AA-/Positive. CRISIL reaffirmed the short-term rating at Crisil A1+. Total bank loan facilities rated were enhanced to Rs. 500 crore from Rs. 400 crore. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 May 2026 | transcript Acquisition, Capex, Guidance, Results | Poly Medicure Limited has informed the Exchange about TranscriptAI summaryPoly Medicure filed the transcript of its Q4 and FY26 earnings conference call held on 25 May 2026 on the audited results for the quarter and year ended 31 March 2026. Management said FY26 consolidated revenue grew 12.3% to INR1,875 crores and Q4 consolidated revenue was INR534 crores, up around 21% year-on-year; standalone FY26 revenue was about INR1,662 crores, up around 4%, with standalone EBITDA of INR446 crores (26.8% margin). Management guided FY27 consolidated revenue of INR2,300-2,400 crores and standalone revenue of INR1,900-1,950 crores, with standalone EBITDA margin of 25-27% and consolidated EBITDA margin of 23-25%. Management guided FY27 capex of INR200-225 crores, and said gross margin could erode by about 200-300 bps from current levels due to crude-linked raw material costs and shipping disruption from the West Asia situation. Management said it acquired Medyneo in Brazil for about USD 40,000, to gain ANVISA and import licences, and expects 20% domestic growth and about 15% international growth in FY27 for standalone business. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 May 2026 | presentation Acquisition, Capex, Guidance, Results | Poly Medicure Limited has informed the Exchange about Investor PresentationAI summaryRevised Investor's Presentation filed on Q4 and FY26 audited standalone and consolidated financial results (year ended March 31, 2026). Standalone FY26 revenue Rs 1,662.5 crore (FY25: Rs 1,601.8 crore); standalone FY26 operating EBITDA margin 27.8%, with Q4 FY26 standalone revenue Rs 443.0 crore. Consolidated FY26 revenue Rs 1,759.5 crore (FY25: Rs 1,669.8 crore), consolidated FY26 operating EBITDA margin 24.4%; consolidated FY26 revenue growth 12.3% and Q4 FY26 consolidated revenue growth 21.3%. Management said the standalone EBITDA margin was close to the higher end of the 25%-27% guidance range; Q4 consolidated EBITDA was impacted by acquisition consolidation and one-time provisions for regulatory and employee costs in a subsidiary. Liquidity of Rs 842.2 crore as at March 31, 2026; capex spend of Rs 296 crore in FY26; 35 products launched in FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 May 2026 | presentation Acquisition, Capex, Results | Poly Medicure Limited has informed the Exchange about Investor PresentationAI summaryInvestor presentation on audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, filed under Regulation 30 of the SEBI LODR Regulations. Standalone Q4 FY26 revenue reached the highest ever quarterly level; standalone FY26 Operating EBITDA margin was 26.8%, near the upper end of the 25-27% guidance range. Consolidated Q4 FY26 revenue grew 21.3% and FY26 revenue grew 12.3%; consolidated FY26 Operating EBITDA margin was 24.4%. Management said gross margin expanded by 130 bps in FY26 and that FY26 capex spend was Rs 296 Crs; liquidity (cash and cash equivalents) was Rs 842.2 Crs as at March 31, 2026. Consolidation of PendraCare Group (from 23 Sep 2025) and Citieffe Group (from 07 Nov 2025) and the acquisition of Medyneo (Brazil) were noted. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 May 2026 | dividend Dividend / buy-back, Results | Poly Medicure Limited has informed the Exchange that Board of Directors at its meeting held on May 25, 2026, recommended Final Dividend of Rs. 3.50 per equity share.AI summaryPoly Medicure Limited's board met on May 25, 2026 and approved audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. The board recommended a dividend of Rs. 3.5 per equity share (70%) of Rs. 5 each for FY 2025-26, subject to shareholder approval. The board approved re-appointment of PricewaterhouseCoopers Services LLP and Oswal Sunil & Co. as internal auditors for FY 2026-27. The meeting started at 12:00 P.M. and concluded at 03:00 P.M. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 May 2026 | board outcome Dividend / buy-back, Results | Poly Medicure Limited has submitted to the Exchange, the Audited financial results(Standalone & Consolidated) for the quarter and year ended March 31, 2026.AI summaryPoly Medicure Limited filed the outcome of its board meeting held on May 25, 2026, approving audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. The board recommended a dividend of Rs 3.5 per equity share (70% of face value of Rs 5) for FY 2025-26, subject to shareholder approval. The board approved re-appointment of PricewaterhouseCoopers Services LLP and Oswal Sunil & Co. as internal auditors for FY 2026-27. The meeting started at 12:00 P.M. and concluded at 3:00 P.M. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Mar 2026 | presentation Acquisition, Capex, Guidance, Results | Poly Medicure Limited has informed the Exchange about Investor PresentationAI summaryPoly Medicure Limited filed its updated Investor Presentation (March 2026) with BSE and NSE under Regulations 30 and 51 of the SEBI LODR Regulations, also posted on the company website. The presentation describes the group as having 15 manufacturing plants in 5 countries, 390+ patents granted, 950+ distributors and supply to 125+ countries. Acquired businesses are profiled: Citieffe (CY24 revenue EUR 17.3 Mn, EBITDA EUR 3.1 Mn), Pendracare Orthopaedics (CY24 revenue EUR 8.2 Mn, EBITDA EUR 0.9 Mn) and a Netherlands cardiology catheter business (CY24 revenue EUR 9.9 Mn, EBITDA EUR 1.4 Mn). Management outlines strategic updates: the second Haridwar plant is commercially operational, the Palwal (Haryana) plant is to be completed by end of FY27, and 5-6 new critical care products are planned for FY27. Management also states that new product launches rose from 19 in FY 2024 to 35 in FY 2025 and that the company plans to double R&D spend in the next few years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Feb 2026 | transcript Acquisition, Capex, Guidance, Legal, Results | Poly Medicure Limited has informed the Exchange about TranscriptAI summaryPoly Medicure filed the transcript of its Q3 and 9M FY26 earnings conference call held on 6 February 2026, on unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2025. Management reported Q3 consolidated revenue of INR494 crores (up about 16.4% year-on-year), consolidated gross margin of 68.4%, operating EBITDA of INR119 crores (24.2% margin, excluding acquisition costs of about INR6-7 crores), and profit after tax of INR71 crores. For 9 months, consolidated revenue was INR1,341 crores (up about 9.1%), with profit after tax of INR256 crores; standalone 9-month EBITDA margin was 26.6%. Management guided that H2 revenue would be about 20% higher than H1 on a consolidated basis, with Q4 revenue expected to exceed Q3, and said capex of INR234 crores was incurred in the first nine months to set up new plants. Management said it received DCGI approval for Intravenous Lithotripsy System and Drug Eluting Balloon products and completed the acquisitions of PendraCare and Citieffe Group. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2026 | presentation Acquisition, Capex, Guidance, Results | Poly Medicure Limited has informed the Exchange about Investor PresentationAI summaryPoly Medicure Limited filed its Q3 and 9M FY26 investor presentation (unaudited standalone and consolidated results for quarter and nine months ended December 31, 2025) with BSE and NSE. Consolidated Q3 FY26 revenue growth was 16.4%, with Q3 Operating EBITDA margin of 24.2% and standalone Q3 EBITDA margin of 26.8%. 9M FY26 consolidated Operating EBITDA and PAT grew 2.7% and 3.6% respectively; 9M Operating EBITDA margin was 25.8%, which management said is close to its 25-27% margin guidance. Cash and cash equivalents were Rs 839.8 crore as at Dec 31, 2025; capex spend was Rs 234 crore in 9M FY26. PAT for Q3 and 9M FY26 includes a one-time Rs 6.8 crore impact from the Revised Labour Code and acquisition-related costs of Rs 6.5 crore (Q3) and Rs 9.71 crore (9M); consolidation includes PendraCare Group and Citieffe Group. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2026 | board outcome Management change, Results | Poly Medicure Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryPoly Medicure Limited's board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with Auditors' Review Reports attached. The board also approved the grant of 2,000 stock options to eligible employees under the Poly Medicure Limited Employee Stock Option Scheme 2020. The board meeting started at 12:45 P.M. and concluded at 2:35 P.M. on 5 February 2026. The OCR text of the results tables is garbled, so the individual revenue and profit figures could not be reliably extracted; the consolidated profit after tax for the quarter appears as 7,860.77 in one line and the nine-month total comprehensive income attributable to owners as 27,743.49, but these are not confirmed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2026 | board outcome Dividend / buy-back, Results | Poly Medicure Limited has informed the Exchange regarding Board meeting held on February 05, 2026 for the approval of Unaudited Financial Results (Standalone & Consolidated) for the third quarter and nine months ended on 31st December, 2025AI summaryPoly Medicure Limited filed the outcome of its board meeting held on 05 February 2026, which approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with Auditors' Review Reports attached. The board also approved the grant of 2,000 stock options to eligible employees under the Poly Medicure Limited Employee Stock Option Scheme 2020, with ESOP grant disclosures enclosed. The meeting started at 12:45 P.M. and concluded at 02:35 P.M. The scanned pages are partly garbled, so the individual financial line items (revenue, profit and EPS figures) could not be reliably read and are not stated here. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Nov 2025 | transcript Acquisition, Capex, Guidance, Results | Poly Medicure Limited has informed the Exchange about TranscriptAI summaryPoly Medicure filed the transcript of its Q2 and H1 FY26 earnings conference call held on 10 November 2025, on unaudited standalone and consolidated results approved by the Board on 8 November 2025. Management said Q2 consolidated revenue was Rs. 444 crores (up about 5.7% year-on-year) with operating EBITDA margin of 26.8% and PAT of about Rs. 92 crores; H1 consolidated revenue was Rs. 847 crores (up 5.3%). Management said the Citieffe Group acquisition (Italy) closed on 6 November 2025 and PendraCare Group (Netherlands) was acquired on 23 September 2025, together adding about Rs. 280 crores of annual revenue. Management revised FY26 guidance: consolidated revenue growth of about 15-16% (versus about 20% earlier), domestic growth of 28-30%, international growth of close to 10%, and operating EBITDA margin of 25-27%. Management guided H2 FY26 revenue of Rs. 1,080-1,090 crores and FY26 capex of over Rs. 250 crores, with Rs. 150 crores spent in H1. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Nov 2025 | presentation Acquisition, Guidance, Results | Poly Medicure Limited has informed the Exchange about Investor PresentationAI summaryPoly Medicure filed its investor presentation on unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Q2 FY26). Consolidated Q2 FY26 revenue was Rs 443.9 Crs, up 5.7% year on year (Q2 FY25: Rs 420.0 Crs); H1 FY26 revenue was Rs 847.1 Crs versus Rs 804.8 Crs in H1 FY25. Consolidated Q2 FY26 Operating EBITDA was Rs 118.8 Crs (margin 26.8%), growth of 2.5%; Q2 FY26 PAT was Rs 93.1 Crs, growth of 5.0%. H1 FY26 Operating EBITDA growth was 2.6% and PAT growth was 14.5%; H1 Operating EBITDA margin was 26.7%, which management said is tracking close to the higher end of its 25-27% margin guidance. Management said the company completed the acquisitions of PendraCare Group (Netherlands) on September 22, 2025 and Citieffe Group (Italy) on November 6, 2025, and had liquidity of Rs 1,109.1 Crs as at September 30, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Nov 2025 | board outcome Results | Poly Medicure Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryPoly Medicure Limited filed the outcome of its board meeting held on 08 November 2025, which ran from 12:00 noon to 01:40 PM. The board approved the unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2025. The filing states the outcome under Regulations 30 and 33 of SEBI (LODR) Regulations, 2015, and notes other business items were also considered. The pages provided include the results statement and a cash flow statement, but the figures are too garbled by OCR to quote reliably. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Nov 2025 | board outcome Results | Poly Medicure Limited has informed the Exchange regarding Board meeting held on November 08, 2025 for declaration of Unaudited Financial Statements (Standalone & Consolidated) for the Second quarter and half year ended 30th September, 2025 AI summaryPoly Medicure Limited filed the outcome of its board meeting held on 08 November 2025, which ran from 12:00 noon to 01:40 PM. The board approved the unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2025. The filing was made under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, to BSE and NSE. The attached pages show the results tables and cash flow statement, but the text is OCR-garbled and the key figures (revenue, profit, EPS) cannot be reliably read. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Oct 2025 | transcript Acquisition, Capex, Guidance, Results | Poly Medicure Limited has informed the Exchange about TranscriptAI summaryPoly Medicure Limited filed the transcript of its investor/analyst conference call held on 25 September 2025 on the proposed acquisition of the Citieffe Group, approved by the Board on 24 September 2025. Management said the company is acquiring 100% of MediStream (Swiss corporation holding Citieffe SRL, Bologna) at an equity valuation of about EUR18.8 million, plus repayment of about EUR4.2 million shareholder loan and assumption of about EUR8 million debt, giving an enterprise value of about EUR31 million (about 10x reported 2024 EBITDA). Management said Citieffe reported 2024 revenue of about 17.3 million and EBITDA of about 3.1 million, with growth of 15% and 14% respectively, and that the Citieffe CEO Pascal Govi will continue in the role. Management said the PendraCare acquisition closed on 23 September 2025 and that it expects Citieffe to double revenue in five years without significant capex, with regular capex of about 1.5 million to 2 million a year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 Sep 2025 | presentation Acquisition, Capex | Poly Medicure Limited has informed the Exchange about Revised Investors PresentationAI summaryPoly Medicure Limited filed a revised investor presentation on its acquisition of the "Citieffe Group", submitted under Regulation 30 of the SEBI LODR Regulations, 2015, in continuation of an intimation given on 24 September 2025. The presentation is titled "Acquisition of Citieffe: Our Pathway to Global Orthopaedic Market" and is dated September 2025. The company states it has 200+ medical devices, 12 manufacturing plants across 4 countries, 334 patents granted, and 125+ countries of presence. The company's 2025-27 plan prioritises expansion of Cardiology, Critical Care, Oncology and Renal Care, along with direct global presence. The pages provided do not state the acquisition consideration or deal size. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Sep 2025 | presentation Acquisition, Capex | Poly Medicure Limited has informed the Exchange about the Investor's Presentation on Acquisition of "Citieffee Group".AI summaryPoly Medicure Limited filed an investor presentation dated September 2025 on its acquisition of the "Citieffe Group", submitted under Regulation 30 of the SEBI LODR Regulations to BSE and NSE on 24 September 2025. The presentation covers the company's background as India's leading MedTech company, with 200+ medical devices, 12 manufacturing plants across 4 countries, 334 patents granted, and 125+ countries served. It outlines a 2025-27 strategy to prioritise Cardiology, Critical Care, Oncology and Renal Care, expand direct global presence, and add new manufacturing plants and an R&D centre. The excerpt reviewed does not include the financial terms, deal size or Citieffe's financial details. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Sep 2025 | transcript Acquisition, Guidance | Poly Medicure Limited has informed the Exchange about TranscriptAI summaryPoly Medicure filed the transcript of its investor/analyst conference call held on 04 September 2025 on the proposed acquisition of PendraCare Group (Netherlands), approved by the Board on 03 September 2025. Management said the target had CY24 revenue of about EUR9.9 million, EBITDA of EUR1.4 million, PBT of about EUR800 thousand and a 74% gross margin. Poly Medicure will acquire 90% of the group for an upfront equity consideration of EUR11 million, plus takeover of inter-group loans of EUR3.2 million to be repaid at closing; net debt of about EUR2.9 million will also be taken over. Management cited implied EV/revenue of about 1.8x and EV/EBITDA of about 13x, plus earn-out payments over four to five years, with the remaining 10% to be acquired in 2030 based on CY2029 EBITDA. Management expects EBITDA synergies of EUR3 million to EUR4 million over three to four years and said the business could reach close to EUR25 million revenue by 2030. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Sep 2025 | presentation Acquisition, Capex | Poly Medicure Limited has informed the Exchange about Investor PresentationAI summaryPoly Medicure Limited filed an investor presentation dated September 2025 on its acquisition of the Pendracare Group, described as a unique interventional cardiology consumable asset in Europe. The filing is submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to BSE and NSE, and is also available on the company website. The pages provided give the company profile (200+ medical devices, 12 manufacturing plants, 125+ countries) and its 2025-27 strategy to expand cardiology, critical care, oncology and renal care verticals. The pages provided do not state the deal size, consideration or closing terms of the acquisition. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Sep 2025 | presentation Acquisition | Poly Medicure Limited has informed the Exchange about Investor s Presentation on Acquisition of Pendracare Group (a unique interventional cardiology consumable asset in Europe.AI summaryPoly Medicure Limited filed an investor presentation dated September 2025 on its acquisition of the Pendracare Group, described as a unique interventional cardiology consumable asset in Europe. The filing was submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to BSE and NSE, and is also on the company website. The visible pages cover the company overview: 200+ medical devices, 12 manufacturing plants across 4 countries, 900+ distributors, and a 2025-27 strategy to expand cardiology, critical care, oncology and renal care verticals. The pages do not state the deal value or terms of the acquisition. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Sep 2025 | board outcome Acquisition, Capex | Poly Medicure Limited has informed the Exchange regarding Board meeting held on September 03, 2025 for Intimation on Acquisition(Incorporation of a Wholly owned step down subsidiary "RisoR Holdings B.V." in amsterdam, Netherlands and updateAI summaryPoly Medicure Limited filed the outcome of its board meeting held on 3 September 2025, which ran from 3.00 P.M. to 4.30 P.M. The board noted the incorporation on 29 August 2025 of RisoR Holdings B.V. in Amsterdam, Netherlands, a wholly owned step-down subsidiary of the company, with authorized and issued share capital of EUR 9. The board approved RisoR Holdings B.V. entering into a Share Purchase Agreement and ancillary agreements with Welling Holdings B.V. to acquire ordinary shares of Pendracare Holdings B.V. and Welling Medical B.V. (the PendraCare Group). After completion, the company, through RisoR Holdings B.V., will own 90% of the economic rights in the PendraCare Group. The company will provide the further details required under SEBI LODR on the day the agreement and shareholders agreement are signed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 Aug 2025 | acquisition Acquisition, Legal | Poly Medicure Limited has informed the Exchange about Acquisition in relation of Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amendAI summaryPoly Medicure Limited filed a Regulation 30 disclosure that the NCLT Allahabad Bench, by order dated August 12, 2025, approved its resolution plan for acquiring Himalayan Mineral Waters Private Limited under the insolvency resolution process. The total consideration for acquiring the target is INR 33.15 crore, paid in cash, for 100% equity shareholding. The filing states all required approvals, including NCLT and Companies Act approvals, have been obtained, and completion is expected within 30 days from the effective date in the resolution plan. The target's turnover was Rs. 4,46,466 in FY 2022-23, Rs. 7,92,50,290 in FY 2021-22 and Rs. 7,91,57,302 in FY 2020-21; its paid-up share capital is Rs. 3,00,00,000. Certain transactions under the resolution plan remain subject to necessary regulatory approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Aug 2025 | transcript Acquisition, Capex, Guidance, Management change, Results | Poly Medicure Limited has informed the Exchange about TranscriptAI summaryPoly Medicure filed the transcript of its Q1 FY26 earnings conference call, held on 08 August 2025, on unaudited standalone and consolidated results for the quarter ended 30 June 2025. Management reported consolidated revenue of Rs. 403 crores, up about 5%, with gross margin of 68.4% and EBITDA of Rs. 106 crores (margin 26.3%); PAT was about Rs. 93 crores versus Rs. 74 crores a year earlier. Management reiterated domestic revenue growth guidance of 30% for FY26 and revised international revenue growth guidance to 5% to 10% from 12% to 15%, citing European weakness and tariff uncertainty. Management kept the EBITDA margin guidance at 25% to 27% and capex guidance of around Rs. 250 crores plus for FY26. Management reported the appointment of Vishal Baid as Executive Director (approved by shareholders) and board approval of P. K. Gupta's appointment, subject to shareholder approval, and two new contract manufacturing contracts. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Aug 2025 | presentation Capex, Guidance, Results | Poly Medicure Limited has informed the Exchange about Investors Presentation with respect to Unaudited Financial Results for the quarter ended 30th June, 2025.AI summaryPoly Medicure filed its investor presentation on unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26). Consolidated revenue rose 4.8% to Rs 403.2 crore from Rs 384.8 crore a year earlier; domestic revenue grew 20.1%. Consolidated operating EBITDA rose 2.1% to Rs 106.1 crore, with operating EBITDA margin of 26.3%, and PAT rose 25.5% to Rs 93.1 crore from Rs 74.0 crore. Management said Q1 operating EBITDA margin is within its FY26 EBITDA margin guidance of 25%-27%, liquidity stood at Rs 1,248.6 crore as at June 30, 2025, and Q1 capex was Rs 95 crore against a FY26 capex budget of Rs 250 crore. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Aug 2025 | board outcome Dividend / buy-back, Legal, Management change, Results | Poly Medicure Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryBoard meeting outcome dated 08 August 2025: unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 approved, with an unmodified limited review report from statutory auditors. Standalone total income for Q1 FY26 was Rs 42,514.22 lacs (Rs 38,425.62 lacs in the year-ago quarter) and standalone profit after tax was Rs 8,792.89 lacs (Rs 7,230.25 lacs); consolidated profit after tax was Rs 9,308.29 lacs (Rs 7,403.94 lacs). Board approved re-appointment of Amit Khosla and Sonal Mattoo as Non-Executive Independent Directors for five years from conclusion of the 30th AGM, and appointment of Pankaj Kumar Gupta as Executive Director for five years from 08 August 2025, all subject to shareholder approval at the ensuing AGM. Board approved grant of 3,400 stock options under the Poly Medicure Limited Employee Stock Option Scheme 2020, and re-appointment of Jai Prakash & Company as Cost Auditors for FY 2025-26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 Aug 2025 | board outcome Legal, Management change, Results | Poly Medicure Limited has informed the Exchange regarding Board meeting held on August 08, 2025.AI summaryBoard meeting outcome dated 08 August 2025: unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 approved, with an unmodified limited review report from statutory auditors. Standalone total income for Q1 FY26 was Rs 42,514.22 lacs and profit after tax Rs 8,792.89 lacs; consolidated total income was Rs 44,490.16 lacs and profit after tax Rs 9,308.29 lacs. Board approved re-appointment of Amit Khosla and Sonal Mattoo as Non-Executive Independent Directors for five years from conclusion of the 30th AGM, and appointment of Pankaj Kumar Gupta as Executive Director for five years from 08 August 2025, all subject to member approval at the AGM. Board approved grant of 3,400 stock options under the Poly Medicure ESOP 2020 and re-appointment of Jai Prakash & Company as Cost Auditors for FY 2025-26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 May 2025 | transcript Acquisition, Guidance, Results | Poly Medicure Limited has informed the Exchange about TranscriptAI summaryPoly Medicure filed the transcript of its Q4 FY25 earnings conference call held on 7 May 2025, on audited results for the quarter and year ended 31 March 2025. Management said consolidated revenue for Q4 was Rs. 440 crores, up about 16.5%, with PAT of Rs. 91.8 crores against Rs. 68.4 crores a year earlier; full-year consolidated revenue was about Rs. 1,670 crores (up about 21.5%) and PAT Rs. 338.6 crores. Management guided for about 20% revenue growth in FY26, with domestic growth of 30-32% and export growth of 12-15%, and EBITDA margin of 25-27%. Management said it expects Renal business growth of about 50% in FY26 and is looking at M&A opportunities; liquidity was Rs. 220 crores as of March 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 May 2025 | board outcome Dividend / buy-back, Legal, Management change, Results | Outcome of Board MeetingAI summaryBoard of Poly Medicure Limited, meeting held 06 May 2025, approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025. The Board recommended a dividend of Rs. 3.50 per equity share (70%) of Rs. 5 each for FY 2024-25, subject to shareholder approval. The Board approved appointment of Mr. Vishal Baid (DIN: 00232727) as Executive Director for five years from 06 May 2025, subject to shareholder approval at the ensuing General Meeting. Mrs. Mukulika Baid (DIN: 02900103), Non-Executive Non-Independent Director, resigned with effect from close of business on 06 May 2025, citing personal reasons. The Board also approved re-appointment of internal auditors, appointment of P.K. Mishra & Associates as Secretarial Auditors for FY 2025-26 to FY 2029-30, and a revision to the ESOP Scheme, 2020 including a new definition of "employee", subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 May 2025 | board outcome Dividend / buy-back, Legal, Management change, Results | Poly Medicure Limited has informed the Exchange regarding Board meeting held on May 06, 2025.AI summaryBoard of Poly Medicure Limited, meeting held on 06 May 2025, approved audited standalone and consolidated financial results for Q4 and financial year ended 31 March 2025. The Board recommended a dividend of Rs. 3.50 per equity share (70%) of Rs. 5 each for FY 2024-25, subject to shareholder approval. The Board approved appointment of Mr. Vishal Baid (DIN: 00232727) as Executive Director for five years from 06 May 2025, subject to shareholder approval at the ensuing general meeting. Mrs. Mukulika Baid (DIN: 02900103), Non-Executive Non-Independent Director, resigned with effect from close of business on 06 May 2025, citing personal reasons. The Board approved re-appointment of PricewaterhouseCoopers Services LLP and Oswal Sunil & Co. as internal auditors for FY 2025-26, appointment of P.K. Mishra & Associates as secretarial auditors for FY 2025-26 to FY 2029-30 (subject to members' approval), and a revision to the ESOP Scheme, 2020 including a new definition of "employee" (subject to shareholder approval). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Feb 2025 | transcript Capex, Guidance, Results | Poly Medicure Limited has informed the Exchange about TranscriptAI summaryPoly Medicure submitted the transcript of its Q3 FY25 earnings conference call held on 03 February 2025 (16:30 IST), covering unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2024. Management said consolidated revenue for Q3 FY25 rose about 24.9% to Rs. 424 crores from Rs. 339 crores, with consolidated EBITDA of Rs. 116 crores (from Rs. 91 crores) and PAT of Rs. 85 crores (from Rs. 65 crores). For nine months FY25, management said consolidated revenue was Rs. 1,229 crores versus Rs. 998 crores (up 23.2%), with PAT of about Rs. 247 crores versus Rs. 190 crores, and that the company is close to its 22-24% revenue growth guidance. Management said CAPEX of about Rs. 222 crores was spent in nine months out of a planned Rs. 300 crores, funded from internal accruals, and that three new plants under construction (including one at Palwal, Haryana) are expected to go live in 18 to 21 months. Management said it received CDSCO licence for a drug-eluting stent, is launching it soon, and has about 50 product SKUs in the pipeline for launch over one to two years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2025 | results Dividend / buy-back, Results | The Company has informed about the Integrated Fillings for the Unaudited Financial Statements(Standalone & Consolidated) for the quarter and nine months ended on 31st December, 2024.AI summaryPoly Medicure Limited filed unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024, approved by the Board on 03 February 2025 and limited-reviewed by the statutory auditors with an unmodified report. Consolidated revenue from operations for the quarter ended 31.12.2024 is printed as Rs 42,421.19 lacs, against Rs 33,959.82 lacs for the quarter ended 31.12.2023 (OCR text is partly garbled, so figures are approximate). Consolidated net profit attributable to equity holders for the quarter ended 31.12.2024 is printed as Rs 8,745.47 lacs (OCR-garbled, to be verified against the original). Basic EPS for the quarter is printed as Rs 8.48 (standalone and consolidated lines are not fully legible in the OCR text). During the nine months, the company issued 53,19,148 equity shares via QIP at Rs 1,880 per share, raising about Rs 99,999.98 lacs, with allotment completed on 22 August 2024; Rs 90,039.50 lacs was temporarily invested in liquid mutual funds pending utilisation. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Feb 2025 | presentation Capex, Results | Poly Medicure Limited has informed the Exchange about Investors PresentationAI summaryPoly Medicure Limited submitted its Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December 31, 2024, dated 3rd February 2025. The presentation states the company has 12 operational plants and 3 under construction, annual capacity of over 1.7 billion devices, and about 70% of revenue from exports. It reports revenue, EBITDA and PAT growth of 22%, 30% and 33% respectively between FY22 and FY24, and a zero net debt balance sheet with significant cash reserves. Management's 2025-27 focus is on expanding cardiology, critical care, oncology and renal care verticals and expanding global direct presence. The pages provided do not include the quarterly financial figures for Q3 FY25 or 9M FY25. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Feb 2025 | results Results | Poly Medicure Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryPoly Medicure Limited filed the outcome of its board meeting held on 03 February 2025, which approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2024. The OCR text is partly garbled, so the exact revenue and profit figures are not reliably readable here; the table lists quarter-ended 31.12.2024 consolidated revenue from operations of about Rs 42,421.19 lacs against Rs 33,959.82 lacs for the corresponding quarter of the prior year. The nine-month consolidated revenue from operations is shown at about Rs 1,18,083.94 lacs (OCR uncertain), against about Rs 94,632.06 lacs for the prior-year nine months. Notes state the results were reviewed by the Audit Committee and approved by the Board, and that the statutory auditors (Doogar & Associates) issued an unmodified limited review report. The company reports a single reportable segment, medical devices; QIP proceeds of Rs 99,999.98 lacs were raised in 2024, with Rs 90,039.50 lacs temporarily invested in liquid mutual funds as of 31 December 2024. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.